Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Unknown 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Pancreatic Neoplasms 6Neoplasms 4Colorectal Neoplasms 4Stomach Neoplasms 3Glioma 2Weight Loss 1Triple Negative Breast Neoplasms 1Solid Tumor Cancer 1Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Refractory Solid Tumors 1Recurrence 1Rectal Neoplasms 1Pseudomyxoma Peritonei 1Peritoneal Neoplasms 1Pancreatic cancer, adult 1Pancreatic Diseases 1Ovarian Neoplasms 1Osteosarcoma 1Oligodendroglioma 1Neuroblastoma 1Neoplasms, Cystic, Mucinous, and Serous 1Neoplasm Metastasis 1Metastatic Pancreatic Adenocarcinoma 1Mesothelioma 1Malignant Solid Neoplasm 1Head and Neck Neoplasms 1Gliosarcoma 1

Interventions

Cyclophosphamide 9Topotecan 5Temozolomide 5Melphalan 5Irinotecan 5Busulfan 5fludarabine 4Granulocyte Colony-Stimulating Factor 4Filgrastim 4liposomal doxorubicin 3fludarabine phosphate 3cabozantinib 3Vincristine 3regorafenib 2pegfilgrastim 2Sirolimus 2Doxorubicin 2Bone Marrow Transplantation 2trioctyl phosphine oxide 1trifluridine tipiracil drug combination 1thymoglobulin 1talazoparib 1selinexor 1seclidemstat 1racotumomab 1poly ICLC 1pembrolizumab 1pegylated granulocyte colony-stimulating factor 1olaparib 1niraparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Sarcoma, Ewing × irinotecan sucrosofate × Clear all
NCT02013336 2022-03-31

Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors

South Plains Oncology Consortium

Phase 1 Unknown
30 enrolled
CNSSarcoma

Neuroblastoma, Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡